Bromocriptine in the treatment of carcinoma of the cervix: a phase II trial.
Twenty patients with advanced carcinoma of the uterine cervix were treated for at least 3 months with 5 mg bromocriptine daily. No remissions were found (95% confidence limits, 0-17%), neither among normo- nor among hyperprolactinemic patients. Twelve had stable disease for 2-9 months with a median of 3 months. The results of this study does not support the hypothesis that bromocriptine possesses any antitumor effect in cancer of the uterine cervix.
D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D001971:Bromocriptine; D011388:Prolactin